Entera Bio Ltd.
NASDAQ:ENTX
Overview | Financials
Company Name | Entera Bio Ltd. |
Symbol | ENTX |
Currency | USD |
Price | 2.72 |
Market Cap | 100,183,584 |
Dividend Yield | 0% |
52-week-range | 0.66 - 3.35 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Ms. Miranda J. Toledano M.B.A. |
Website | https://www.enterabio.com |
An error occurred while fetching data.
About Entera Bio Ltd.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD